--Poster presentation proposes targeting PPARG for the treatment of muscle-invasive urothelial cancer (MIUC) may help overcome resistance to immunotherapy--
Michael L. Meyers, M.D., Ph.D. to join as Chief Medical Officer; Daphne Karydas promoted to President and Chief Financial Officer; Michaela Bowden, Ph.D., promoted to Chief Development Officer; and Jigar Raythatha joins the Board of Directors
Led by GordonMD® Global Investments LP and Pfizer Ventures, financing to support advancement of FX-909, a first-in-class PPARG inhibitor, into the clinic in 2023, along with continued development of Flare’s platform and pipeline of novel transcription factor targets in oncology
Robert Sims, Ph.D., Chief Scientific Officer and co-founder of Flare Therapeutics, will present the discovery of its clinical candidate, FX-909, at the AACR Annual Meeting in Orlando, FL
Robert Sims, Ph.D., Chief Scientific Officer and co-founder at Flare Therapeutics, will present a company overview at the upcoming Guggenheim Healthcare Talks Oncology Day in New York, NY
Daphne Karydas, Chief Operating Officer and Chief Financial Officer of Flare Therapeutics, will present a company overview at the Piper Sandler 34th Annual Healthcare Conference being held in New York, NY
Molecular Real-World Data (RWD) from 3,000+ individuals with advanced and metastatic urothelial cancer highlight Peroxisome Proliferator-Activated Receptor Gamma (PPARG) as a lineage defining transcription factor is foundational to Flare’s precision oncology approach
Company has pioneered ‘switch site’ approach to uncover druggable regions within well validated, but elusive, transcription factors that are master regulators of gene expression